Smarter Drugs: A Focus on Pan-Specific Monoclonal Antibodies

ISSN： 1173-8804

Source： BioDrugs, Vol.25, Iss.6, 2011-12, pp. : 357-364

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Trends in the Development and Approval of Monoclonal Antibodies for Viral Infections

By Reichert Janice M.

BioDrugs, Vol. 21, Iss. 1, 2007-01 ,pp. : 1-7

Adis International

Access to resources Recommend Favorite

Monoclonal Antibodies in Cancer Treatment: A Review of Recent Progress

By Alpaugh K. von Mehren M.

BioDrugs, Vol. 12, Iss. 3, 1999-09 ,pp. : 209-236

Adis International

Access to resources Recommend Favorite

Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies: Concepts and Lessons for Drug Development

By Mould Diane R. Green Bruce

BioDrugs, Vol. 24, Iss. 1, 2010-02 ,pp. : 23-39

Adis International

Access to resources Recommend Favorite

The Potential of Monoclonal Antibodies to Reduce Reperfusion Injury in Myocardial Infarction

By McKenzie M.E. Gurbel P.A.

BioDrugs, Vol. 15, Iss. 6, 2001-06 ,pp. : 395-404

Adis International

Access to resources Recommend Favorite

Targeted Immunotherapy for Staphylococcal Infections: Focus on Anti-MSCRAMM Antibodies

By Otto Michael

BioDrugs, Vol. 22, Iss. 1, 2008-01 ,pp. : 27-36

Adis International

Access to resources Recommend Favorite